ADLM 2024

Actionable Insights for Improved Decision-Making!

Visit us and learn more about our innovative solutions at the ADLM 2024 in Chicago from July 30 to August 1 at booth 318!

BIOTYPE provides a robust portfolio of molecular cancer diagnostics to support hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio comprises IVD assays for clinical diagnostics, RUO assays for translational and clinical research, and a benchtop system for automated molecular profiling. Our 4h workflow ensures rapid and precise cross-dimensional analysis of actionable biomarkers such as FGFR2/3, POLE, and MSI, in alignment with current guidelines. Discover our latest tests designed to deliver reliable results efficiently.

Interested in learning more about BIOTYPE?

Contact Dr. Norman Gerstner, Dr. Abhishek Aich or Marina Levichkova and discover more about BIOTYPE's strong portfolio and our unique benchtop system for molecular multiplex testing – the MODAPLEX platform and our CDMO services!

We look forward to all the inspiring talks!